Thrombin Receptor Antagonist: Advantages in Percutaneous Coronary Intervention?
DAVID MOLITERNO, University of Kentucky, Lexington
REFERENCE: American College of Cardiolgy New Orleans, March 24th Late Breaking Trials
An oral thrombin receptor antagonist, SCH 530348 has proved safe and effective, and may be better than conventional anti-coagulation treatments for patients
…An oral thrombin receptor antagonist, SCH 530348 has proved safe and effective, and may be better than conventional anti-coagulation treatments for patients